http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Study of Milling GH3039 on Milling Force with Ceramic Tool WG300
Jinghe Li,Wang Xi,Min Qi,Yubo Liu 보안공학연구지원센터 2015 International Journal of u- and e- Service, Scienc Vol.8 No.5
To nickel base superalloy in dry cutting, the milling experiment be done in the four-axis machining center with ceramic tool WG300 is in order to know the influence of cutting speed to chip morphology through the macroscopic observation on chip by optical microscope and the analysis of chip morphology. Then, focus on the machining features of GH3039, reasonable orthogonal test be designed, after which getting the influence of different level’s value to milling force and its change law based on the range analysis of experiment datum.
PDEA-coated Magnetic Nanoparticles for Gene Delivery to Hep G2 Cells
Hanwen Sun,Xin-jun Zhu,Lian-ying Zhang,Xiangling Gu,Jinghe Wang,Jing Li,Yancong Zhang 한국생물공학회 2013 Biotechnology and Bioprocess Engineering Vol.18 No.4
Poly(2-(diethylamino)ethyl methacrylate) coated magnetic nanoparticles (PDEA-MNPs) were synthesized as a new gene nanocarrier to delivery plasmids (pEGFPN1and pRL-TK) into human hepatoma (Hep G2) cells. The PDEA-MNPs shows the pH-sensitive property. These nanoparticles are positively charged at acidic pH and negatively charged at neutral or alkaline pH. The PDEAMNPs exhibited a low cytotoxicity in Hep G2 cells. PDEA-MNPs could bind and protect DNA from DNase I degradation. The transfection study demonstrated that the PDEA-MNPs could carry plasmid into Hep G2 cells and exhibited a high gene transfection efficiency. These results indicated that the novel magnetic nanoparticles could enhance gene transfection in vitro and hold the potential to be a promising non-viral nanodevice.
Pengfei Li,Lan Chen,Yan Ni,Jiaqi Liu,Donglin Li,Jianxin Guo,Zhihua Liu,Shuangling Jin,Yan Xu,Zhiqiang Li,Lu Wang,Xiaonong Bin,Jinghe Lang,Ping Liu,Chunlin Chen 대한부인종양학회 2021 Journal of Gynecologic Oncology Vol.32 No.2
Objective: To compare 5-year disease-free survival (DFS) and overall survival (OS) rates oflaparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) forstage IB1 and tumor size <2 cm with visible or invisible tumors. Methods: We retrospectively compared the oncological outcomes of 1,484 cervical cancerpatients with IB1 and tumor size <2 cm on final pathology, who received ARH (n=899) or LRH(n=585) between January 2004 and December 2016. Patients were divided into visible tumorsubgroup (ARH: n=668, LRH: n=444) and invisible tumor subgroup (ARH: n=231, LRH:n=141) according to tumor type. Results: LRH and ARH showed similar 5-year DFS and OS rates (93.3% vs. 93.1%, p=0.997;96.2% vs. 97.5%, p=0.351) in total study population. LRH was not associated with worse5-year DFS rate (hazard ratio [HR]=0.96; 95% confidence interval [CI]=0.58–1.58; p=0.871)or OS rate (HR=1.37; 95% CI=0.65–2.89; p=0.409) by multivariable analysis. In the visibletumor subgroups, LRH and ARH showed similar 5-year DFS and OS rates (91.9% vs. 91.9%,p=0.933; 95.0% vs. 96.9%, p=0.276), and LRH was not associated with worse 5-year DFS orOS rate (p=0.804, p=0.324). In the invisible tumor subgroups, LRH and ARH also showedsimilar 5-year DFS and OS rates (97.3% vs. 97.1%, p=0.815; 100% vs. 99.5%, p=0.449), andLRH was not associated with worse 5-year DFS rate (p=0.723). Conclusions: Among patients with stage IB1 and tumor size <2 cm, whether the tumor isvisible or not, the oncological outcomes of LRH and ARH among cervical cancer patients arecomparable. This suggests that LRH may be suitable for stage IB1 and tumor size <2 cm withvisible or invisible tumors.Trial Registration: International Clinical Trials Registry Platform Identifier: CHiCTR180017778